Randomized Clinical Trial of Vitamin D3 Doses on Prostatic Vitamin D Metabolite Levels and Ki67 Labeling in Prostate Cancer Patients | Zendy

Dennis Wagner | Zendy; Dominique Trudel | Zendy; Theodorus van der Kwast | Zendy; Larisa n | Zendy; Angeline A. Giangreco | Zendy; Doris Li | Zendy; André H. Dias | Zendy; Monique Cardoza | Zendy; Sanda Laszlo | Zendy; Karen Hersey | Zendy; Laurence Klotz | Zendy; Antonio Finelli | Zendy; Neil Fleshner | Zendy; Reinhold Vieth | Zendy

Open Access

Randomized Clinical Trial of Vitamin D3 Doses on Prostatic Vitamin D Metabolite Levels and Ki67 Labeling in Prostate Cancer Patients

Author(s) -

Dennis Wagner,

Dominique Trudel,

Theodorus van der Kwast,

Larisa n,

Angeline A. Giangreco,

Doris Li,

André H. Dias,

Monique Cardoza,

Sanda Laszlo,

Karen Hersey,

Laurence Klotz,

Antonio Finelli,

Neil Fleshner,

Reinhold Vieth

Publication year - 2013

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2012-4019

Subject(s) - medicine , prostate cancer , vitamin d and neurology , prostate , calcitriol , urology , metabolite , randomized controlled trial , vitamin , prostatectomy , context (archaeology) , prostate specific antigen , endocrinology , cancer , biology , paleontology

Vitamin D3 might benefit prostate cancer (PCa) patients because prostate cells can locally synthesize the active hormone calcitriol.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research